Skip to content
DataLookout
Menu

NCT06643000

Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis

StatusUnknown
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
  2. Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
    • Study sites: 1 to 2
    • Primary completion date: Jan 2025 to Mar 30, 2025
    • Study completion date: Mar 2025 to May 30, 2025
    • Start date changed from estimate of Oct 2024 to Dec 20, 2024
    • Study description expanded, about 1 word
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

OS
Timeframe: the time between the date of enrollment and the date of death from any cause

Secondary (3)

TTF
ORR-LM
CRR

Arms and interventions

Triple therapyExperimental

furmonertinib combined with bevacizumab and pemetrexed

Drugs: furmonertinib

Sites

2 sites in 1 country